Observational study identifies clinical features and mortality from acute mesenteric ischaemia in Covid-19 cases, suggesting challenges for treatment.
Data on acute mesenteric ischaemia (AMI) in patients with Covid-19 are limited. We studied the clinical profile and outcome of patients presenting and treated for AMI and Covid-19 infection. This retrospective, observational study was done at a single tertiary care centre in India from May 2021 to April 2022. Ten patients (8 males; median age 57 years) with confirmed Covid-19 and AMI diagnosed on the basis of clinical and radiological criteria were included in the analysis. Associated comorbid conditions were present in 8 of 10 patients. The median interval from diagnosis of Covid-19 to onset of gastrointestinal symptoms was 11 days, with abdominal pain being the most common. Seven patients underwent surgical resection, while 3 patients were managed conservatively. Two patients were on antithrombotics before the development of AMI and had less severe involvement. Four patients died in hospital. AMI in Covid-19 infection is associated with morbidity and mortality. Previous antithrombotic use does not prevent the development of AMI but possibly reduces its severity.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: